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2INTRODUCTION
Carriers of recessive gene disorders are increasingly 
a focus of public health interventions, facilitated by 
the growth and greater social acceptance of new 
genetic and reproductive technologies. The NHS-
coordinated twin antenatal and neonatal screening 
programme for sickle cell and thalassaemia 
disorders, formalised in 2002 in England, identifies 
thousands of ‘healthy carriers’ (adult and children) 
each year. Current estimates suggest that there are 
240,000 sickle cell carriers (predominantly among 
people of African and African-Caribbean origins) and 
214,000 carriers of thalassaemia disorders (largely 
of Greek, Turkish, Cypriot, South and South-East 
Asian, and Arab origins). 
While newborn screening helps early therapeutic 
intervention for babies affected by sickle cell 
disorders, it also raises significant social, ethical, 
psychological and medical issues by inadvertently 
picking up some type of carriers (Laird, Dezateux 
and Anionwu,1996; Oliver et al., 2009). (The current 
heel prick test for newborn babies does not identify 
thalassaemia disorders)There are currently no 
consistent guidelines supporting how parents are 
informed about their baby’s carrier status and the 
level of counselling and support offered to them to 
address any potential concerns (Lempert 2004). 
Interestingly, carrier screening of babies/children 
sits uncomfortably with the cautious approach 
recommended by the Human Genetics Commission 
in (2010), since it has no therapeutic benefit and 
potentially compromises their right to reproductive 
choices as an adult. 
Antenatal screening for sickle cell and thalassaemia 
variants, in contrast, whilst simultaneously 
connected to individual choice and preference, can 
be viewed as representing a more ‘preventative’ 
approach. The stated policy aim is: 
… to facilitate informed choices in screening, identify 
women/couples at risk of pregnancy with sickle cell 
or thalassaemia disorders and provide appropriate 
referral and care for prenatal diagnosis, so that 
women/couples can make informed choices as to 
whether to continue the pregnancy or request a 
termination (Harcombe and Armstrong, 2008:582). 
As is clear from similar policy documents, 
antenatal carrier screening presupposes and 
supports the notion of reproductive choice. 
However, paradoxically, its success is closely 
associated with earlier and/higher uptake 
of prenatal diagnosis aiming to reduce the 
incidence of live births of babies affected by these 
variable, though life- threatening conditions 
(Greengross et al., 1999: 3; Williams, Alderson 
and Farsides, 2002); measured in ‘incremental 
cost effectiveness ratios for affected live births 
prevented’ (Zeuner et al, 1999:79). It is hardly 
surprising that public health policies supporting 
prenatal diagnosis are bound to be contested 
in relation to wider social values underpinning 
disability/impairment (Kerr, Cunningham-Burley 
and Amos, 1998; Shakespeare,1999). Equally 
importantly, antenatal screening brings the 
intimate sphere of reproduction and family/kinship 
life of individuals/couples irrespective of their 
ethnic background (cf. Down’s syndrome) under 
clinical and state surveillance. Carrier screening 
for haemoglobinopathies, in particular, focuses 
attention on culture, religion and genetic literacy of 
‘at risk communities’. Recent policy move towards 
pre-conceptual screening, for example, assumes 
that individuals from ‘high risk communities’ want 
to know their carrier status and will/should make 
‘rational’ choices about not having children with 
another carrier. 
Historically in the UK, sickle cell and thalassaemia 
have been associated with homogenised views 
of minority ethnic groups, often marginalized 
as a ‘minority’ health issue. With shifts in family 
formation and plural, ethnic identities located 
transnationally, old labels denoting ‘ethnic origin’ 
may no longer be a reliable predictor of who might 
carry a particular trait (Dyson 2005) or the presence 
of different traits within the same family over a 
period of time. Equally, the identification of carriers 
from majority white ethnic backgrounds prompts 
us to think more critically about the assumed links 
between ethnicity, race and genetics being straight 
forward and predictable (Carter and Dyson, 2011).
3OUR RESEARCH 
Previous policy oriented and sociological research 
on sickle cell and thalassaemia disorders has 
tended to focus on how carrier status impacts 
on reproductive choices or decisions related to 
antenatal screening. We know little about how 
being a ‘healthy carrier’ impacts on people’s ideas 
about health and illness or, more broadly, their 
sense of social relationships and identity at different 
phases of the life-course (Kerr, 2005). 
The main aims of our two year research, funded by 
the Economic and Social Science Research Council 
(January 2012 to December 2013), were to:
 § understand how individuals from diverse ethnic 
backgrounds make sense of being a sickle cell or 
thalassaemia carrier at different phases of the 
life-course;
 § analyse whether being identified as a carrier is 
associated with notions of health and illness for 
one’s self and significant relationships; 
 § explain how these understandings about 
being a carrier might/might not be related to 
one’s ethnic identity and shift over time (for 
individuals and communities);
 § explore whether ‘being a carrier’ influences 
significant decisions about seeking partners and 
reproductive choices within extended families 
in relation to current and potential screening 
pathways; and 
 § disseminate findings with potential significance 
for policy and practice for both professionals 
well as members of the communities. 
Methods used
The research using qualitative methods was carried 
out in two overlapping phases. We first conducted 
four workshops (PW) with professionals (n=26), 
focusing on their perceptions and experiences of 
providing support to carriers from diverse ethnic 
backgrounds. The participants ranged from a 
paediatric haematologist, haemoglobinopathy 
specialist nurses and counsellors, midwives, 
community support workers from voluntary sector 
organisations, centre managers, a young people’s 
nurse for long term conditions, and outreach and 
communication officers working across the NHS 
and the voluntary sectors. Participants also had 
an opportunity to comment on the new suite 
of carrier leaflets introduced on request from 
the Outreach Office of the National Screening 
Programme for Sickle Cell and Thalassaemia. This 
helped further focus our discussion on issues of 
information and support. We also held four focus 
group discussions (FFFG) with family members and 
friends (n= 29) who knew a carrier (but were not 
a carrier themselves), to understand what they 
thought about the experiences of carriers within the 
communities. 
The second phase involved in-depth interviews 
with a theoretical sample of 57 participants (33 
women, 24 men) between 17-70 years of age, 
recorded digitally and translated (n=6)/transcribed. 
Each participant was interviewed once, and 25 
of the 57 interviews involved a range of family 
relationships (eg parent/ child, husband/wife, 
uncle/niece, cousins). The age range allowed us to 
explore the different policy pathways and personal 
circumstances leading to the identification of 
being a carrier, covering different phases of the 
life-course across the dataset. The participants 
represented five broad ethnic backgrounds African, 
African-Caribbean; South Asian (Indian, Pakistani); 
Greek, Cypriot, Turkish and white or plural heritage 
with complex trans-national family histories. 
Only six participants chose to speak in a language 
other than English (Urdu/Hindu/Punjabi), and their 
interviews were translated into English. 
A thematic guide was used for conducting the 
interviews drawn from relevant literature (screening 
policy, health service research, sociology and 
anthropology), and the focus group discussions with 
family, friends and professionals. For the purposes 
of this summary, we used thematic analysis based 
on biographical case studies to provide an overview 
of the similarities and differences within and across 
families of carriers. Each case study focused on the 
personal context within which the meaning and 
implications of carrier status are located, whilst 
relating it to the wider social and policy context. 
Moving from the individual to the wider social and 
structural factors (including the impact of policy or 
interaction with professionals) avoids the danger 
of predefining ethnicity as the only/main factor 
underpinning the experience of carriers. 
Presenting the findings
A summary of the main findings is presented 
below which, we hope, policy makers and service 
providers across the NHS and voluntary sectors 
will find useful. It is not our intention to provide 
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understandings’ of genetics rather to translate ideas 
across different and complex social and experiential 
frameworks within which people make sense of 
the ‘diagnosis’ of being a carrier. In doing so, we 
highlight various tensions which have the potential 
of undermining the stated aims of the screening 
policy and practice. This is not to deny the examples 
of good practice, highlighting the sensitive and 
appropriate support provided by professionals to 
carriers and their families, in the face of emotionally 
challenging situations. However, our concern is to 
build on previous debates and further encourage 
reflexive practice, based on a wider understanding 
of the history, aims and social implications of carrier 
screening on one hand; and a better understanding 
of the personal context within which individuals 
across (majority and minority) ethnic groups 
interpret carrier ‘diagnosis’ and make moral choices 
related to genetic risk on the other. 
In focusing on the tensions evident in current policy, 
we want to specifically support a move away from 
the ‘deficit model’ of science/genetics (and public 
health), wherein minority ethnic communities 
are often blamed for a ‘lack’ of knowledge/ 
understanding of genetics and genetic risk. The 
‘deficit model’ treats health information within a 
rationalist model of autonomous behaviour (see 
Gregory and Miller 2000). The assumption being 
that more extensive dissemination of information to 
‘at risk’ communities can lead to ‘rational’ individual 
life-choices and, thereby, prevention of births of 
children with these disorders. Here, ‘lay people’ 
are perceived as passive recipients of knowledge, 
while their individual interests are assumed as being 
similar to those of the community ‘at risk’. 
We argue that in promoting public engagement 
with genetic disorders, with a view to bridging 
the gap between professional/scientific and lay 
perspectives, it is important to recognise and 
address the significant personal, social and ethical 
issues surrounding carrier screening that are 
often left unaddressed within policy guidance and 
literature. A shift from the ‘deficit model’ is crucial 
for making public engagement more inclusive 
and equitable by involving different communities 
and forms of knowledge (policy, lay as well as 
professional), and broadening the debate on carrier 
screening before any future policy initiatives and/or 
any changes to current policy are undertaken. 
We now turn to our main findings, presented in two 
sections. The first section summarises four main 
intersecting themes discussed in the professional 
workshops. These relate to communicating test 
results and providing support; the conundrum of 
‘healthy carriers’; focus on ethnicity and ‘lack of 
understanding’; and balancing care with screening 
(prevention). The next section provides a bird’s-
eye view of the main themes generated by the 
in-depth interviews with carriers. These themes 
focus on: the salience of a trait and engagements 
with genetic risk; the context of testing and quality 
of support; challenging stigma within competing 
sources of knowledge; responses to hypothetical 
and real scenarios of screening/testing; and what 
is wrong with the consanguinity argument? We 
conclude with a few recommendations for policy 
and practice. 
THE MAIN FINDINGS: PROFESSIONAL 
WORKSHOPS
Communicating test results, counselling 
and support 
We begin by connecting the practical implications 
of disclosing test results with broader philosophical 
discussions about the meaning of diagnosis. 
Discussions in our workshops with practitioners 
suggested that there is no consensus on how the 
results of new born carrier status are disclosed 
in practice across geographical sites (Ulph et al, 
2014). Parents might be told by letter, in person or 
on the phone by a receptionist that their baby is a 
carrier, raising concerns about the quality of such 
communication and lack of follow up, as reflected 
below: 
Contrary to policy guidelines (NHS, 2011:4) and 
assumptions of most parents in our sample, 
professionals were not sure whether GPs always 
receive information about new born carrier results:
I’m always concerned about the result of … the 
trait carrier, because …even if they are informed 
about the baby’s result, they’ll be told not to worry 
because the trait doesn’t cause problem. … by the 
time the baby, the child gets to teenage the mum 
will have forgotten what she was told…. So when 
the child gets into their teens, she or he doesn’t 
know whether she has the trait or whatever …. 
(PW4) 
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a London borough where a photocopy of the 
new born test result is sent to the health visitor, 
parents and the GP simultaneously. But perhaps not 
surprisingly, the specialist nurses and counsellors 
reflected a lack of confidence in non-specialist 
colleagues and GPs disclosing carrier results to 
adults and providing required counselling:
The overlap between the two categories - also 
reflected in the ‘family and friend’ focus group 
discussions and in-depth interviews - impinges 
on a fundamental semantic issue of whether or 
not a trait constitutes a diagnosis in itself and the 
implications thereof. 
‘Healthy carriers’: a Pandora’s box? 
The International Classification of Diseases (ICD-
10 version 2010) subsumes traits within the 
diagnostic categories (D56.3 for thalassaemias 
and D57.3 for sickle cell disorders). However, in 
practice, heterozygotes (carriers) seem to receive 
a quasi- diagnosis of having a ‘trait’ that may not 
have any implications for their own health. Even 
though clinicians recognise that Beta thalassaemia 
carriers might have anaemia due to their red blood 
cells being slightly smaller, this is generally not 
acknowledged in the information leaflets endorsed 
by the NHS. The leaflet for Hb AS mentions that ‘in 
very rare situations’ carriers might face possible 
health issues and provides appropriate advice 
(www.sct.screening.nhs). On the whole, the main 
implication and thrust of the information is on 
… one of the problems is the IT (…) it would be 
wonderful if this research would kind of endorse 
this point … that the result to be in the child’s 
record with the GP and for there to be some specific 
intervention that the GP should do to just remind 
the child, and at the moment that’s kind of, that’s 
definitely not (happening) ….(PW4)
… with all due respect, I mean in general practice 
(laughs)… I find mostly a lot of GPs don’t really 
understand the differences between a trait and 
a (condition). And sometimes, they have been 
telling people they have the condition when they 
don’t, and there are times when they do have the 
condition and they are telling them that they are 
carriers…. (PW4).
explaining the risk of passing on the gene/disorder 
to the children if the partner also is a carrier. 
Several professional participants raised the issue of 
carriers complaining of symptoms, especially those 
with Hb AS, that might be disregarded by their GPs, 
raising doubts about the idea of a ‘healthy carrier’. 
The following observation by a voluntary sector 
professional well summarises the point:
Clinically oriented participants did think that sickle 
cell carriers, in particular, might have symptoms 
even though their status did not trigger a crisis. This 
acknowledgement was often backed by research 
in the US (given the racialised history of sickle cell 
and the politics of health insurance, clinical opinion 
is divided on the potential risk of pain and sudden 
death among carriers): 
The acknowledgement that carriers might 
experience symptoms depending on their 
haemoglobin type composition came with a caution 
that the diagnostic label might be appropriated by 
‘patients’ to ‘get round the system’. Diagnostic 
labels generate symbolic meaning and in this 
context, the semantic association between the 
trait and the condition creates room for doubt, 
‘confusion’ and alternate explanations of the 
meaning of ‘being a carrier’. At the same time, a 
…they (…) get the results, and then it’s, ‘You’re 
healthy, go on along your way’. … we’re hearing it 
a lot more where traits are saying, “You know what, 
I’m getting the symptoms”. … I’m not a medical 
person, none of us here (organisation) are …, so we 
do say again, ‘Go back to your GP’. But I think it’s 
kind of ingrained in the GPs to say, ‘Well actually, 
no, you’re a healthy carrier’. That’s the definition 
almost, it’s not just a carrier, you are a ‘healthy 
carrier’, and if you’re getting the aches in your 
joints, whatever, well you’re just getting old, aren’t 
you? I do think we need to do something about it. 
… (laughs)… basically you have all those red blood 
cells that could potentially sickle as well, but 
wouldn’t warrant a crisis. Because … if we look on 
American studies and research we can see that 
there’s loads of research done for carriers, because 
in America I think a lot of people who are carriers 
have some form of conditions and very open to say, 
‘I have this condition, in relation to being a trait’ 
(PW2).
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rather than genetic transmission per se generates 
a critique of the underlying policy intentions within 
the broader racialised history of health for particular 
minority ethnic groups (discussed on page 11).
A focus on ethnicity, ‘lack of understanding’ 
and informed choice
Often professionals found it hard to understand why 
despite counselling and co-ordinated information 
disseminated within relevant minority ethnic 
communities, and women and their partners during 
antenatal period in particular, they were not able 
to grasp the implications of their carrier status for 
passing on the trait/condition to their children. 
Sounding exasperated, one of them commented: 
Others were more forthright about the ‘need’ for 
counselling to be more ‘targeted’: 
The notion of ‘informed choice’ often reflected 
default cultural values of risk and rationality; 
challenged by perceived ‘deviant’ cultural practices 
of minority ethnic communities defined as ignorant 
and lacking in knowledge and understanding. 
However, such criticisms (or indeed counter-
criticisms) were not confined to professionals of 
a particular majority or minority background. The 
… we have very good screening coordinators who 
do a lot of counselling and that’s great at the time, 
but when I follow them up neonatal … with a (baby) 
carrier, they’re shocked. Now, whether they lose 
the information somewhere between the ten weeks 
of screening antenatal and the five or eight days 
postnatal, I don’t know. But they’re often really 
shocked ….(later) …they’ve misinterpreted what 
they were told, forgotten … or they’re so tired 
postnatally that they hadn’t quite taken on board 
that we were screening for this…. (PW2)
…when you give the information it’s reinforcing, and 
sometimes even your tone of voice has to change. 
You’ve given them the information but when it 
comes to saying, “Now are, are you taking this on 
board?” … you know, it’s all body language isn’t it? 
The look, the direct look, the, you know, and you’re 
actually pointing it out slowly, precisely, clearly, 
and then when you’ve finished …. So you’re making 
sure that they’re making an informed choice if it 
comes to the antenatal screening …. (PW2)
following reference to consanguineous marriages 
among families of Pakistani origin by a (white) 
participant provides only one example of a long 
standing thorny issue that continues to divide public 
opinion, defining the limits of ‘rational’ choice:
However, another (white) participant (from 
a different site within the same group, PW2) 
cautioned: 
This prompted what might seem like the obvious 
conclusion from another participant: 
Finally, some participants reflected more critically 
on the need for professionals to challenge the taken 
for granted ‘matching’ of haemoglobinopathies to 
particular ethnic groups: 
… we can have young adults with the condition and 
we find that the, you know, they’re still marrying 
within the family and they’re still getting people 
over from Pakistan and they’ve seen, you know, 
the sibling and all the things that have happened 
and yet they will still bring somebody in …..…. 
(PW2)
‘It’s not really consanguinity. It’s the gene. You’ve 
got to make sure (to emphasise), it’s the gene that 
you’ve got to be careful of’. 
‘That’s why we never … link cousin marriage to the 
counselling, because … people can come up with 
the impression that, as long as you don’t marry 
your cousin, it’s fine, and that’s totally not the case’ 
(PW2). 
I had a real horrible case a couple of years ago where 
there was a girl who was Jamaican Indian … and she 
was a beta thal trait, and her partner was Caribbean, 
he was sickle cell trait. They’d gone to the antenatal 
clinic early, from about seven weeks … it was a newly 
qualified midwife, didn’t send a referral through to 
the sickle cell centre, cos just assumed thalassaemia 
and sickle didn’t cause a problem. By the time I got 
this referral, the girl was thirty-eight weeks’ gestation. 
After I gave her all the information, she, she just got so 
upset, she delivered two days later…. And it was just 
mistake after mistake after mistake. And it was really, 
really sad because … you know, between the cultures, 
‘it needs to be black on black or Asian on Asian’…. …, I 
think last year alone, we saw about eight beta thal 
girls, white, white girls, white British (PW1).
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perception of sickle cell and thalassaemia disorders 
being an attribute of particular ethnic/racial groups 
as mutually exclusive categories can result in 
significant emotional disruption and mistrust within 
relationships. The following example shared by one 
of the professionals captures well, what sociologists 
describe as, geneticisation of kinship (Finkler et al, 
2003):
Despite a partial recognition of the presence of 
white carriers reflecting genetic variance within 
broad ethnic groups, rather than simply a result 
of ‘mixed’ ethnic relationships, the dominant 
health promotion literature continues to portray 
these conditions as an attribute of minority ethnic 
groups. Given the long history of racialization of 
health of minorities in the UK, this often results 
in reinforcement of stereotypes; whilst creating 
internal differences along the fault lines of ‘genetic 
responsibility’ and responsible citizenship (ie 
preventing births of children with these conditions). 
As explained later, this can lead to a culture of 
community groups perpetuating this dominant view 
within which having a child with the condition can 
be stigmatised, raising serious ethical issues about 
the rights of the disabled within our society and 
how we make judgements about lives ‘worthy of 
living’ (Shakespeare, 1999). 
Balancing care with a focus on screening 
Most of the information and informal counselling 
to carriers was being provided by specialist 
services and community workers within voluntary 
sector organisations. Both sectors have suffered 
significant shortfalls in funding, affecting the 
networks of support and services within the 
community, which have often being built up over 
many years and much struggle. Some professional 
participants suggested that screening in the UK 
currently receives more funds, at the expense of 
… and the sister was tested and found to have a 
sickle cell trait. And she said, ‘I went to my mother, 
…, sat my mother down. I said, ‘Could you tell me 
what happened thirty-four years ago (laughter) 
that you didn’t tell me about?” And the poor 
woman said “What are you talking about?” She 
said “Who’s my father?” And she said “I beg your 
pardon!” She says, “Well I’ve just been told I’ve got 
sickle cell trait and there’s only black people who 
have sickle cell trait, so who’s my father?” (PW4)
haemoglobinopathy services, which are believed to 
be patchy. 
These findings resonate closely with the 
experiences of carriers identified through different 
pathways (at times, outside the UK) and having 
very different experiences in relation to the twin 
screening policy introduced in 2002. It is to these 
experiences we now turn.
THE LONG TERM IMPLICATIONS OF 
BEING IDENTIFIED AS A CARRIER 
Salience of a trait and engagements with 
genetic risk
Interviews with carriers highlighted the significance 
of the biographical context, of which ethnicity is 
only one dimension, underpinning the meaning 
and importance of having a trait/being a carrier. 
A trait (for a recessive gene disorder) can remain 
invisible or unknown in a family for generations; 
and once disclosed, its meaning shifts over time 
with changes in the life-course of individuals within 
the context of significant relationships (family and 
friends). Hence, biographical risk unfolds in time 
and might be at odds with the notion of genetic 
risk being static and predefined for an individual 
(as represented in the inheritance diagrams used in 
the information leaflets and genetic counselling). 
Consider the following example from one of the 
interviews capturing moments across three time 
periods (T1, T2 and T3). 
Anne (not her real name), a woman of Greek 
–Cypriot origin in her 50, had always ‘known’ 
since she was a teenager that she was a beta 
thalassaemia carrier. However, she said that it was 
‘verified and clarified’ only when she was pregnant 
with her first child: 
… but here we are more screening driven and that 
in the expense of … the full blown conditions are 
quite left behind. Because most … if we look on 
the different services, I think the different services 
are commissioned with the screening rather than 
care … and if we have care, they put the element of 
screening as well. So it, the screening takes more of 
the service nationally than the care itself (PW1).
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Cyprus and the family assumed that he was not 
a carrier (though it transpired that the results of 
siblings had been mixed up, at the time). By the 
time Anne married, she knew two cousins living in 
Cyprus, diagnosed with beta thalassaemia major 
and had heard of stories about an aunt and a 
cousin losing babies. The significance of the trait 
now focused on the risk of having a child with the 
condition, since thalassaemia seemed pervasive 
in different sides of the family and ‘rife’ within the 
community:
(T3) Knowing a close friend whose child had beta 
thalassaemia, Anne felt ‘lucky’ that neither of 
her children were affected by the condition. Her 
concern for her son as a carrier only surfaced once 
he grew up and started dating. Yet, she would not 
expect him ever to start a relationship by asking 
his girlfriend, ‘Do you carry thal?’ With arranged 
marriages (families introducing the couple to each 
other) declining as a social practice, she did not 
imagine a couple ‘standing at a bar and asking 
each other whether they were carriers’. Besides, 
raising the issue, in itself, assumes that both are 
committed to a long term relationship with an 
intention to have children. Hence, people leave it 
(T1) … I remember the doctor coming back then 
(teenage) and saying, ‘Everything’s fine…, you’ve 
got that thalassaemia thing (trait) but that’s 
quite common in Greek people,’ and that was it. I 
paid that much attention to it because he was 
very dismissive, and I never ever questioned it or 
researched it or thought anything more but it was 
always at the back of my mind. 
…she (sister) had the trait, her husband has the trait, 
my husband’s sister has the trait, my husband’s 
sister’s husband has the trait. So they’d both had 
… (to make difficult decisions surrounding prenatal 
diagnosis (PND)). … I was mature by then. I was 
in my twenties (but) had no concern because I 
knew from (in-laws)… that my husband wasn’t a 
carrier. But I went to hospital, received a phone call 
and they said to me, ‘You’ve been found to carry… 
beta-thalassaemia trait, and you need to send your 
husband in for a blood test’ …. I think, I was about 
four months (pregnant) by then, and they rang me 
and I… fell to pieces obviously and they said, ‘You’re 
both carriers ….’
until later. As she put it, young love is about, ‘… 
you hold hands, skip down the road and face it 
together’…. I don’t know if it’s enough to break 
people up, it certainly didn’t occur to me to …. … 
even if I’d found out he was a carrier beforehand I 
would have stayed with him and thought, ‘Right, 
we’re going to get through this together’.
Hence, what might seem like an ‘irrational’ choice 
or a ‘risk minimising’ strategy from a clinical 
perspective, especially where both partners know 
each other’s carrier status, often signals a test of 
a relationship and moral credibility of self. It is, 
therefore, important to understand genetic risk 
within the social domain of significant relationships. 
Such risk minimising rather than risk averting 
strategies are not confined to people from less 
educated, traditional, religious or minority ethnic 
backgrounds, as we know from literature on 
other genetic disorders such as cystic fibrosis. 
Different families or members of the same extended 
family might choose either of these strategies. 
For example, Jacob, a man of African-Caribbean 
heritage in his 40s, perceived his relationship with a 
white woman as averting the risk of having a child 
with sickle cell anaemia, since, to him, ‘Caucasian’ 
and ‘English people don’t get it’. In contrast, his 
brother, also a carrier, said that he would never 
date a white woman since he could not identify 
with them. Jacob had always known that he was a 
carrier and had lost two close relatives to sickle cell 
anaemia. He said: 
An acceptance of such an essentialised view 
of sickle cell disorder being an attribute of 
African/ black ‘origin’ or heritage can hardly be 
attributed to the realm of ‘folk’ or lay knowledge 
(‘misinformation’). Rather it reflects a long history 
of sickle cell being the example of a racialised 
disease within medicine and policies related to 
public health in the UK and the US (Duster, 2003). 
At the same time, a positive affirmation of sickle 
cell being part of a black identity has long been 
part of the struggle for seeking citizenship rights 
in the UK (Nelson 2011; Anionwu and Atkin, 2001), 
… that’s also part of your build-up as you’re growing 
…, because I did know … the chances of me having 
children, full-blown sickle cell by (...) one of my 
own origin … I didn’t want that…. … I don’t think it’d 
been fair to bring a child into the world knowing its 
chances of reaching twenty-one are slim.
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(Fulwilley, 2011). Stories of the infamous Tuskegee 
Syphilis trials (conducted by the US Public Health 
Department between 1932- 1972) morphed into 
transnational rumours about sickle cell anaemia 
being a product of a post-colonial conspiracy to 
wipe out the African race. According to John; 
Four participants narrated different versions 
of this story. Even though such rumours may 
not be widespread, they manage to generate 
mistrust in the system and might serve as post 
facto explanations for being treated differently by 
healthcare professionals. 
Further, higher incidence of mixed ethnic 
marriages/relationships (one in ten according to 
a recent analysis) and serial monogamy pose a 
significant challenge to the bureaucratic ways of 
identifying ‘family origin’. A greater proportion of 
individuals will have more than one partner over 
their life-course; and children/step children in a 
family might inherit different traits. Further, this 
results in discontinuities in family health histories 
and (genetic) narratives of inheritance, in contrast 
with the fixed notions of ethnicity and of bilateral 
inheritance (from fathers and mother’s sides) 
assumed within clinical genetics and the inheritance 
diagrams. 
The context and pathways of testing and 
finding the ‘wrong trait’
The level of information and support provided to 
carriers varied significantly with how and when a 
person was identified. Women and men who were 
identified through the antenatal screening pathway 
generally received more information (face-to-face 
and written). Yet, contrary to policy guidelines, only 
couples identified as potentially ‘at risk’ or who, in 
fact, had a baby with a condition received formal 
counselling and support. Needless to mention, men 
whose partners were not carriers ‘fell through’ the 
net of antenatal carrier testing pathway, unless 
their carrier status was already known or disclosed 
following the birth of a child who was a sickle cell 
‘… well my theory is…, well back in the like World 
War I’s and II’s there was a lot of genetic testing 
and germ warfare…. …so I, me personally, I think 
it was manufactured to kill off a race or kill off a 
nation or whatever and then it got out of hand, you 
know what I mean?’ 
carrier. Women who were identified as having a 
Hb variant but whose partners were not carriers 
were often left to seek further information on their 
own, especially where the trait did not match their 
perceived ethnic/racial profile. For example, Nora, 
a woman of Black-British heritage, in her 30s, was 
sent for sickle cell screening along with her partner 
when she was pregnant (about eight years ago). 
She recalled:
Nora felt that once they found that she and her 
husband did not have a sickle cell trait, there was no 
further discussion:
Returning to the issue later, she complained: 
Nobody had explained the possibility that her 
child might also be a carrier. Two women of Indian 
origin, who were thalassaemia carriers and whose 
proficiency in English was limited, thought that they 
had beta thalassaemia major (condition). One of 
them, Tejinder, who was in her 20s and had moved 
… to get tested and he came back clear and I… and 
I came back with thalassaemia trait. From there 
I went to the doctor and … the doctors didn’t 
really know much more, to be fair. I think it was 
me, I’d gone on, online and found out what it was 
and thought it was more to the Indian side of my 
(father’s side) family where it came from and…
It was just kind of … it wasn’t as important as 
the sickle cell. ‘The main issue here, what you’ve 
been tested for is sickle cell, because if you’re 
both a carrier then these are the implications. 
But you haven’t got that, you’re fine’. You’ve got 
thalassaemia trait …. I mean they didn’t say, ‘It’s all 
right’, but it … wasn’t made an issue of.
But again, when you find out if you’ve been 
diagnosed with a condition, so to speak, I think you 
should be fully informed. … I mean the whole point 
was to test that the baby was OK, but at the same 
time I’m, I’m the mother so a bit more information 
should be given to me… how’s it going to affect me? 
But I think being pregnant at the time, my main 
concern was that the baby’s fine, so I didn’t think 
much more of it. But thinking back on it now … if 
anyone’s told, you’ve got any type of condition, you 
should be sat down and maybe counselled slightly 
just to say how it could possibly affect yah.
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to the UK following her marriage, was a mother of 
two small children under five years of age. She said 
that even though she was healthy apart from being 
anaemic and breathless at times, she worried about 
the impact thalassaemia might have on her health 
in future. She was particularly concerned about 
potential health implications for her children since 
she had breast fed both and wanted to find out 
whether they needed any special diet to keep them 
healthy. Having been identified during antenatal 
care, she had received a haemoglobinopathy 
card specifying beta thalassaemia trait. She had 
also been given an information leaflet in Punjabi. 
However, she had no experiential knowledge about 
thalassaemia and, since her husband was not a 
carrier, there was no further discussion on the issue 
with the antenatal nurse or others involved in her 
care. Even though her GP spoke Urdu/Punjabi, she 
had not raised these concerns with him, reconciling 
to the fact that she had an ‘illness’. Rather than 
dismiss it as a ‘cultural’ issue or a result of her ‘lack 
of English’ and ‘lack of understanding’ about the 
condition (the deficit model), Tejinder’s experience 
reiterates the need to focus on the language 
of genetics and to tailor the information to the 
circumstances of an individual/couple. Receiving 
information, face to face or in the form of a leaflet/
other resources, is a process rather than a discrete, 
one off activity or event that happens at a point of 
time. Hence, it is important to enable the person to 
relate the technical information within the context 
of their own life, and to signpost carriers to the 
right professionals in case they have doubts or any 
concerns in future. 
Men and women, especially those who were older 
and found out their carrier status inadvertently, 
outside the antenatal and new-born screening 
pathways, had received minimal information with 
little support to address any potential anxieties 
related to health. Some of them were not sure why 
they had been given a haemoglobinopathy card 
and whether they could donate blood (since they 
had a blood disorder). For example, one of the older 
participants Mary, of Ghanaian origin and in her 60s, 
had found out that she had a beta thalassaemia trait 
when she was in her 50s, during a hospitalisation. 
Nobody had bothered explaining what that meant. 
She had known a relative and a close neighbour 
affected by sickle cell anaemia and, not knowing 
anything about thalassaemia, having a ‘blood 
disorder’ conjured images of a painful illness and a 
fear of death. Her GP dismissed her fears, leading 
her to find out more through her network of friends 
at church and a voluntary sector organisation. 
Interestingly, rather than worry about the carrier 
status or health of her children, her concerns 
focused on the health of her grandchildren. They 
seemed healthy but since they did not know the 
‘symptoms’ of thalassaemia, she thought, they 
might miss it and the condition might resurface in 
the future generations. Given that she herself did 
not know where she got it from, the idea of genes 
‘skipping a generation’ fitted well within her own 
narrative, as it did for those who tried making sense 
of the elusive category of a trait and an inherited 
blood disorder. 
A trait recedes into the background or might be 
treated as an insignificant detail of one’s health 
history where the individual or couple have moved 
away from the phase of childbearing either because 
of their age or by choice. James, who was in his 50s 
(Jamaican family and professional background), 
already had a daughter from a previous relationship, 
as did his second wife. Both had decided against 
having any more children. Being a carrier had never 
been an issue in his life and he did not remember 
having concerns about his daughter being a carrier 
or having been tested. Instead, he used it as a 
positive sign of his identity (distinguishing him from 
the white majority) in following terms:
Interestingly, the only white participant (in her 50s), 
Jackie, had been diagnosed with beta thalassaemia 
trait in her 40s, when she already had teenaged 
children. She had a lingering concern about 
having passed it on to them (in case they ever got 
together with a man from an ‘ethnic’ background 
who happened to be a carrier). Being in the health 
profession herself, she felt that they should make 
their own choice about carrier testing as an adult. 
One of them decided to have a test while the other 
did not want to know. 
Where a child was known to have a blood disorder 
in a family other children/siblings were more 
likely to have been tested. This was not the same 
in the case of a parent/s or a child being a carrier 
(where no close family member was affected by 
I know it sounds silly but it, it’s, it’s one of these 
things you sort of live with. I never really consider 
that, ‘Oh! Sickle cell … is a problem so I need to 
be considering this and I need to be considering 
that. I see sickle cell … a positive note, as a natural 
defence for malaria ….
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the condition). We did not include any parents/
grandparents who themselves had the condition; 
except for one man of Nigerian origin in his 50s, 
Osman. He had been diagnosed as a carrier (AC) in 
Nigeria, in his 30s, and had suffered from persistent 
painful crises as a child. Following his move to 
the UK, he survived serious health crises events 
including a diagnosis of sarcoidosis and pulmonary 
embolism, and was eventually re-diagnosed as 
having a complex haemoglobinopathy based on 
a DNA analysis. He had three children from two 
previous relationships, and each had been tested. 
Osman felt a responsibility to share his knowledge 
about sickle cell with his extended family in Nigeria 
and set up a local support group for families 
affected by the condition in his town in England. 
He believed that the diagnosis saved his life since 
he was able to understand and manage his illness 
better with treatment. It is hardly surprising that 
he was more sympathetic towards carriers who 
complain of having painful crises and believe that 
they might develop symptoms as they get older. 
While he differentiated between being a carrier and 
having the condition in terms of severity, for him, 
these belonged on a continuum rather than as types 
or an absence/presence of a disorder. 
Carriers who experience significant symptoms, 
especially those who have Hb AS and complain of 
feeling very cold, achy and easily tired believed that 
carriers can have ‘mini crises’ in extreme weather 
conditions or under social and emotional stress – 
challenging the notion of a ‘healthy carrier’ as being 
misleading. Such responses can suggest potential 
confusion over the idea of a ‘carrier diagnosis’, as 
identified by some practitioners. In an extreme case, 
Linda, a woman of African-Caribbean origin in her 
late 50s, strongly felt that all this ‘misinformation 
out there that sickle cell trait is not significant 
and does not cause any health issues’ needs to be 
addressed. She had been complaining to her GP 
about headaches, muscular pains, memory and 
concentration issues and the GP dismissed her 
symptoms as being psychosomatic. Linda said:
Linda (like others in her situation), acknowledged 
In my experience, my Ex GP Dr. …. tried to relay 
them as being psychosomatic. I believe that he 
thought that I was imagining the pain or that it was 
all in my head. I could not understand how I could 
have such power and why, of all the wonderful 
things to imagine, I would imagine a pain. 
the role of extreme weather, dehydration, stress 
as well as difficult personal circumstances as 
contributing to her symptoms. Her perseverance 
led the GP to refer her for an MRI scan that did not 
show any lesions and she was told that she had 
cluster headaches and myalgia. She then searched 
for information online and found ‘scientific papers’ 
(journal articles) suggesting that sickle cell carriers 
can experience muscular aches or a sickling crisis if 
they are dehydrated; could have headaches, silent 
strokes and memory issues. She set up a blog and 
initiated an online support group with membership 
across UK and the US, where carriers share their 
experiences and concerns. The important issue here 
is not whether Linda’s symptoms were clinically 
‘real’ or imaginary. Rather, a lack of recognition 
of her symptoms led her to seek information and 
support online, diminishing her faith in professional 
expertise and support within the NHS. This is not to 
deny that others, especially parents and siblings, 
who knew someone close with the condition, 
disagreed with their clinician’s suggestion that their 
symptoms might be caused by their carrier status. 
Challenging stigma within competing and 
contested sources of knowledge
Literature suggested that carriers of sickle cell 
disorders might face discrimination in seeking 
employment or insurance due to controversial 
evidence surrounding the likelihood of sudden death 
under extreme circumstances. However, this seems 
to reflect the specific economic and political history 
of sickle cell anaemia in the US (see Franklin and 
Atkin, 1986). Discrimination against employees, 
servicemen and sportspersons who were carriers 
resulted in the 2008 Genetic Information Non-
discrimination Act, prohibiting employers from 
discriminating on the basis of genetic information, 
and against mandatory genetic testing. 
None of the participants in our sample reported 
facing discrimination on the basis of their carrier 
status. This largely reflected the fact that they 
did not consider this information to be relevant 
for inclusion in forms for employment, insurance 
or mortgage, unless a form specifically asked 
whether the individual suffered from ‘any blood 
disorders’. In one family, a young person who was 
a beta thalassaemia carrier had had to disclose 
her carrier status but had a positive outcome for 
her application to join the Forces. While none 
reported discrimination, two participants shared 
some concerns. One was a mother who had a child 
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with sickle cell anaemia and thought disclosing 
her carrier status might push up her insurance for 
air travel. The other, Anina, a woman of Gujarati-
Indian origin in her 20s, felt that it was unfair that 
her fertility treatment had been withheld until her 
husband had also been tested. She observed:
The British Committee for Standards in Haematology 
recommends screening women/ couples being 
considered for infertility and those having 
assisted conception (NHS Screening Programmes, 
Information for healthcare professionals: 9). 
However, In the above case, the GP had not 
explained why they had to wait for treatment until 
her husband was tested. Further, she and a friend 
(another participant) were given the impression 
that if both partners were carriers, they had to have 
pre-implantation genetic diagnosis of embryos 
alongside IVF. Contrarily, some of the professionals 
suggested that the private fertility clinics may not 
follow the same guidelines, reiterating the need 
for national guidelines on the rationale and ethics 
of carrier testing/not testing within the context of 
fertility treatment. 
Even though participants often differentiated 
between having the condition and being a carrier/
having a trait, a conflation between the two terms 
might lead to culturally specific stigma associated 
with blood/genetic disorders, especially for those 
who have no experiential knowledge of these 
conditions. Hence, the terms ‘thalassaemia major’ 
for the condition and ‘minor’ for a trait can be 
confusing for those who are not familiar with the 
condition. The historically and culturally specific 
association of SCD with ‘full blown’ and ‘blood 
disorder’ (terms commonly used by professionals 
Yeah they explained about the one in four chance 
of the actual thalassaemia rather than the trait, 
yes so I think we understood that. But then since 
then, I wanted to go on… my fertility treatment and 
because of both of us having thalassaemia (trait), 
they said there was a possibility that we wouldn’t 
get any Clomid and then they referred us to a 
geneticist.
(Why did they say that?)
Well I think my GP said she had never come 
across a couple who both had thalassaemia trait 
and she wasn’t sure that we could (have fertility 
treatment)…, I think it was a mix up. I’m not very 
happy with it... but that is another story.
and community members) leads to images of HIV/
AIDS and sexually transmitted diseases, resulting 
in an extension of stigma for some younger men of 
African origin. 
Given its potential discontinuities in family histories 
and the invisibility of the trait, despite the high 
carrier incidence in the minority ethnic communities 
represented in our sample and stories about stigma 
(narrated by professionals and corroborated by 
family members and friends) across broader 
ethnic groups, a majority of participants had little 
experiential knowledge about the condition. Equally, 
this marks a dissonance between the links between 
collective/community history, knowledge about 
the condition and the family/individual histories. 
This seemed like a surprising finding that partly 
reflects our sampling strategy and might be helpful 
in reorienting the emphasis away from simplified, 
bureaucratic ideas of ‘community genetics’ and 
ethnicity currently informing policy and practice 
(for a review and ethnographic case studies see 
Raz, 2010; Shaw, 2011). As pointed out by Alex, a 
young professional in his 20s from a Greek-Cypriot 
background, ‘ … if you target a community, it puts 
a stamp on it to say there is something wrong with 
… this community… and officially it is so serious, we 
need to … root them out …. I think, … where stigma 
could come from’. Whilst at the Greek school that 
he attended, and within his own extended family, 
nobody mentioned thalassaemia in derogatory 
terms, he had noticed that in the wider community 
parents who had a child with thalassaemia were 
blamed. 
Anne, given her wider experience, was more 
critical of the ethical issues underpinning such an 
attitude within her community. She remarked (with 
reference to the Greek screening policy): 
I think what’s happened over the years is …, hardly 
any babies are born now in the Greek community 
because of the CVS…. And, and I have heard it said 
that those who do carry thalassaemia feel almost 
like they’re the forgotten cause. Because, because 
it’s an illness that people are trying to eradicate 
it’s almost, horrible as it is to say, it’s almost as if, 
‘Oh, once we get rid of this batch we can actually 
eradicate this….’ 
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This is a poignant reminder that we need a 
wider ethical debate on the role of genetic 
technologies (antenatal/prenatal/preimplantation/
preconceptual) and collective attitudes to 
disability and difference underpinning state 
policies supporting an expanding continuum 
of ‘reproductive choice’. At the same time 
routinisation of technology leads to shifts in 
attitudes and expectations and any change in 
current policy must follow on from a proper public 
consultation on improving and widening access 
to services. This demands a critical engagement 
with public response as an outcome of these 
consultations which, as suggested by the scenarios 
below, cannot be taken at its face value for 
justifying ‘giving them what they want’, particularly 
since current screening polices are often defended 
on the basis of public demand and the offering of 
choice. 
Scenarios of screening/testing
Out of the various real and hypothetical scenarios 
of carrier testing presented to the participants, 
there was a surprisingly overwhelming support 
for offering a test to teenagers/young adults 
before leaving school/sixth form. Those who 
endorsed mandatory screening in schools (wrongly) 
subsumed it within the category of vaccinations 
that they thought children ‘had to have’ (without 
parental consent). Others believed that early 
testing (conflating carrier status with the condition) 
must be good since it would improve treatment. 
However, as suggested by their own experiences, 
and reflections on the impact of such a policy on 
actions/reproductive decisions, they did not think 
knowing their carrier status would impact on who 
they might have a relationship/children with. 
We knew only one couple who had separated under 
family pressure but eventually got back together. 
We can extend the logic to pre-conceptual testing 
and why it may still not lead to the expected 
… that’s how people that carry thalassaemia feel, 
that I’ve spoken to..., if we’ve got a thousand, 
which there isn’t, but if we’ve got a thousand, once 
they’re gone there won’t be a thousand to replace 
them because we’ve used the CVS and we’re slowly 
eradicating…. …, now my friend (has a child with 
thalassaemia) has often said to me, you know, 
‘They don’t care about us… … you really have to 
push (for support), you have to really insist, yeah’.
outcomes. This option also raises ethical concerns 
about our attitudes to ‘imperfect’ births and the 
potential stigma being generated against carriers 
within a new form of genetic exogamy, the 
rule of exclusion in seeking partners who might 
be genetically ‘affected’. In communities with 
a longstanding tradition of endogamy, carrier 
status can have serious repercussions for the 
moral identities of individuals, especially women, 
as ‘damaged goods’ and the social standing of 
families who will not be able to fulfil the obligation 
of reciprocity of which consanguineous marriages 
is only a part (Rozario, 2013; Shaw, 2011). The final 
section below summarises the internal contestation 
and a critique of the focus on consanguinity by 
professionals within practice. 
What is wrong with the consanguinity 
argument? 
Most importantly, a focus on consanguinity locates 
risk within ‘relatedness’ as marrying within cousins 
rather than the potential carrier status of a partner. 
This is a long standing problem (Atkin and Ahmad, 
1997). Such a notion of relatedness is complex 
where the structural principle of both parallel and 
cross cousin marriages results in more distant 
‘cousins’ related on either side marrying. The 
pragmatic response of ‘not marrying a cousin’ does 
not exclude the possibility of marrying a carrier and 
having a child with thalassaemia, thus resulting in 
mistrust for the biomedical explanation. Second, 
it is not validated by an experiential framework 
where parallel and cross-cousin marriages might 
have been followed within an extended kin group 
for generations without any visible signs of an 
inherited blood disorder. Hence, it does not explain 
why other couples of the same generation who are 
cousins have perfectly healthy children and other 
ethnic groups who do not follow this tradition, such 
as Greek, Cypriot Turkish or Gujarati-Hindus or 
whites still have children with thalassaemia. Third, 
genetic risk implies uncertainty and the doctors 
cannot be certain about the risk for each couple in 
each pregnancy. This creates a space for alternate 
explanations, risk minimising strategies alongside 
a critique of the biomedical framework on genetic 
risk. At the same time, such a critique of medical 
framework does not exclude the possibility of self 
-reflection and change. 
Most couples of Pakistani origin had experienced the 
(potential) birth of a child with thalassaemia within 
a broader critique of professional attitudes towards 
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consanguinity that made them feel responsible for 
their child’s condition rather than simply an assault 
on their cultural heritage. While doubting the logic 
of biomedical explanation that consanguinity 
caused their child’s illness for reasons explained 
above, their own experience of caring had prompted 
a move for change within the extended family. 
There was greater sharing of information in close 
extended families affected by the condition, 
prompted by prospective marriage arrangement of 
younger siblings, often transnationally. This shift 
in cultural practice appears in conjunction with 
a scathing critique of professionals who openly 
blame the birth of a child with thalassaemia in 
families of Pakistani origin to consanguinity. The 
logical message for professionals from Sakina, and 
other parents caring for a child with thalassaemia, 
was to tell everybody, ‘No matter who you marry, 
get tested’. She was particularly upset since her 
parents had gone out of their way to listen to their 
GP’s advice and married her to someone who was 
neither a cousin nor Pakistani. 
IMPLICATIONS FOR POLICY AND 
PRACTICE AND RECOMMENDATIONS 
Our summary captured some of the complexity 
of biographical contexts within which individuals 
are identified as carriers and negotiate notions of 
risk. As we have seen, ethnicity was frequently 
evoked but was not the only consideration when 
explaining how people made sense of their carrier 
status. We now outline the broad implications of our 
findings for policy and practice alongside specific 
recommendations. In doing so, we specifically 
challenge the ideas which associate health 
information with a rationalist model of autonomous 
behaviour; and equate ‘at risk’ individuals with 
‘at risk communities’. We argue that policy needs 
to move away from its current emphasis on 
instrumental rationality underpinning screening and 
ideas of reproductive choice, to a broader focus on 
the significant personal, social and ethical issues 
generated by identifying carriers of a recessive gene 
disorders. 
Implications for policy and practice
 § A trait can remain invisible in families for 
generations. Hence, despite the higher incidence 
of sickle cell disorders or thalassaemias in 
particular ethnic groups, individuals/families 
might have little or no experiential knowledge 
about the condition. Nor can assumptions about 
community awareness, in which knowledge 
about sickle cell and thalassaemia is seen as 
taken-for granted as collective resource, be 
guaranteed. 
 § Individuals across ethnic groups experience 
personal (biographical) genetic risk as unfolding 
and changing over time, within the context 
of significant relationships, experiential 
knowledge, professional communication as 
well as historical and cultural factors. This 
contrasts with the static notion of genetic risk 
as given and unchanging over the course of an 
individual’s life (as represented in the genetic 
diagrams explaining inheritance). 
 § Despite policy guidelines, communication of 
carrier results and the level of information and 
support are variable, depending largely on the 
pathway through which carriers are identified as 
well as the geographical location of the service. 
This leads to inconsistencies in the experiences 
of individuals within and across families. 
 § Provision of appropriate counselling remains 
largely confined to antenatal care for women/
couples identified as being ‘at risk’ for having 
a baby with a haemoglobinopathy. This leaves 
many carriers to fend for information on their 
own, with no support. 
 § Much one-to-one information and support 
for carriers who are anxious about different 
aspects of carrier status is provided by the 
local voluntary sector organisations (working 
closely with the statutory sector/ NHS). The 
role of voluntary and community organisations 
in providing information and personalised 
support better suited to the individual needs, 
beyond the remit of ‘reproductive choice’, 
cannot be overstated. Third sector organisations 
have an excellent track record of listening to 
and engaging with local communities. Their 
community workers are easily accessible, 
well known and trusted in the communities 
they serve. However, this support is currently 
threatened by significant reductions in funds 
available to them. This is despite NHS changes 
highlighting the value of involving voluntary 
organisations in Clinical Commissioning Groups 
as well as Specialist Commissioning. 
 § Professionals as well as community members 
reflect a lack of confidence in General 
Practitioners in explaining the implications 
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of carrier results and addressing particular 
concerns of carriers about potential symptoms 
and prospective health issues. This is a long 
standing problem. 
 § The idea of a ‘healthy carrier’ is a caricature 
that fails to take into account the potential 
emotional, physical and social impact of a 
‘diagnosis’ and the likelihood that some carriers 
might experience symptoms. Equally, it fails 
to recognise the anxiety some parents might 
face whose baby/child has been identified as a 
carrier. 
 § Professional perceptions of sickle cell disorders 
and thalassaemia being an attribute of minority 
ethnic groups/culture (rather than a genetic 
condition per se) can reinforce stigma for 
carriers and undermine their confidence in 
biomedical explanations as well as the credibility 
of healthcare professionals. 
 § A policy focus on ‘at risk communities’ (rather 
than individuals) is similarly unhelpful and 
misleading. While aiming at challenging stigma 
and promoting choice, it can inadvertently 
strengthen misperceptions and stereotypes 
such as the association of sickle cell anaemia 
with AIDS in some communities of African 
origin; or the attribution of thalassaemia to 
consanguinity among Muslims of South Asian 
origin (thereby reducing genetics to culture).
 § The use of language and terms by healthcare 
professionals, such as ‘full blown’ for sickle 
cell anaemia and ‘major’/‘minor’ for beta 
thalassaemia and trait respectively, only seeks 
to perpetuate a conflation between trait and the 
condition and the specific health implications of 
being a carrier.
 § With around 1 in 10 couples in England living in 
mixed ethnic relationships and an increasing 
proportion likely to marry/ have children with 
multiple partners over a life-course, parents 
and (half) siblings within the same family can 
inherit different traits or complex haemoglobin 
variants. Identifying ethnicity/ family origin as 
a marker of ‘at risk’ individuals in practice will 
increasingly be less reliable.
Recommendations for policymakers 
1. Given the pivotal role of local voluntary sector 
organisations in providing information and 
support to carriers and families with carrier 
children and/or siblings with a disorder, we 
recommend ring-fencing of relevant funds 
by local Commissioning Groups to ensure 
continued support for carriers in the long term. 
Current shortfalls in funding are undermining 
the networks of support and services within 
the community, which have often been built 
up over many years of long struggle. Once they 
are gone, they will be difficult to re-invent 
and a valuable resource central to care in the 
community will be lost. 
1.1  There is an urgent need for revising and 
implementing current policy guidelines 
regarding carrier screening and testing 
across various pathways of care (both 
private and public sectors), with a view 
to improving access to information and 
counselling. In addition, documentation of 
test results in the health record of individuals 
in primary care needs to be standardised. 
1.2  The national haemoglobinopathy cards 
are a useful aide de memoir for individuals 
and families in constructing their genetic 
histories over the long term. We recommend 
their use be standardised across adult 
and paediatric services, with the type 
of haemoglobinopathy variant clearly 
mentioned, as advised by the British Society 
for Haematology (Ryan, Bain, Worthington et 
al., 2010: 47).
1.3  With demographic shifts in mixed heritage 
relationships and greater national and 
international geographical mobility, the 
Family Origin Questionnaire may not 
necessarily be an appropriate indicator 
of the risk profile of individuals. Local 
Commissioning Groups need to budget 
for appropriate training of professionals 
enabling them to understand and appreciate 
the relevance of ethnic origin, without 
relying on visible difference (skin colour) as a 
marker of genetic risk. 
1.4  We recommend a wider recognition in 
policy guidelines of the complex emotional, 
social and ethical dilemmas thrown up by 
identifying recessive gene disorders. Such 
recognition should also inform the training 
and practice of professionals. Carrying a 
trait, for example, has implications beyond 
reproductive choices and can assume 
meaning at different points of time across 
16
the life course. While this is acknowledged in 
some policy documents, it is not reflected in 
the information leaflets or support provided 
to a majority of carriers. 
1.5  Given the twin screening policy, it is a State 
responsibility to conduct and/or synthesise 
evidence from clinical trials on potential 
symptoms or health implications for ‘healthy 
carriers’. Sociological research prompts us 
to recognise that a diagnosis in itself might 
result in subjective experience of symptoms 
and significant health concerns (for self 
or close relatives including children and 
grandchildren) over time. This needs to be 
recognised and addressed by professionals, 
with appropriate signposting for further 
information and support.
2. We recommend wider and more inclusive 
community engagement and debate on the 
benefits as well as the social and ethical 
dilemmas posed by identifying infant carriers 
as an unintended consequence of the newborn 
screening policy. This is in tune with the advice 
of the British Society for Human Genetics (2010), 
and (previously) Human Genetics Commission 
(2006). Apart from the complexity of informed 
consent and parental rights, this involves 
reproductive rights and the right ‘not to know’ 
for the child as a future adult. Any change 
in policy must follow a proper consultation 
with a cross section of stakeholders across 
communities, without assuming an easy fit 
between individual and community interests. 
 2.1   We recommend clear policy guidelines for 
recording and following up the carrier status, 
once the cohort of babies/children identified 
as carriers through newborn screening reach 
the age of maturity. While most parents 
accept that passing this information on to 
their children is a parental responsibility 
to be shared with their GP, there is little 
confidence in how well these records are 
being maintained or updated. Current 
consent procedures might also need to 
change, as neo-natal screening is presented 
to parents as identifying those with the 
condition rather than carriers of the trait. 
3. Professionals and counsellors need to identify 
alternate frameworks to ‘the deficit model’ 
when addressing lay/professional differences 
in explanations and understandings of genetic 
risk. It is important to recognise that carriers 
(like patients) are not passive recipients of 
information on genetic risk, and will often 
seek plural sources to validate their own 
experience and interpretation depending on 
their life situation. Acknowledging this can 
benefit practitioners in addressing the individual 
context within which the implications of carrier 
status, genetic risk and reproductive choice are 
understood and negotiated. 
 3.1   We strongly recommend changes to the 
current information leaflets available to 
carriers on potential health implications of 
being a carrier. The thrust of the current 
information leaflets endorsed by the NHS 
Screening Programme is on the importance 
of being tested with a view to avoiding/
preventing a potential birth of a child with 
the condition. The idea of a ‘healthy carrier’ 
is, at best, an unhelpful caricature that fails 
to acknowledge the range of other concerns 
carriers might have/develop over the course 
of time. 
 3.2   The booklet ‘Screening Tests for you and 
your baby’, in particular, provides a sketchy 
and one-sided overview of why screening 
for sickle cell and thalassaemia is being 
offered to mothers and fathers (giving the 
impression that the test in itself is important 
for the baby’s health: p.8). There are no 
positive messages about the level of support 
and care available for children with these 
variable conditions. Importantly, there is 
no acknowledgement of the emotional 
and ethical issues raised by the process of 
confronting a decision to have a PND which, 
as we know, can be emotionally distressing 
for both women and their partners. Clearly, 
there is a need to balance an emphasis on 
screening/testing with positive messages 
of supportive care for potential babies born 
with these conditions, as outlined in the 
section on Down’s syndrome in the same 
booklet. 
4. Whilst there might be support, at a hypothetical 
level, for pre-conceptual testing within 
communities (at birth, in schools or as adults), 
there is no simple co-relation between knowing 
one’s carrier status and seeking a non-carrier 
partner. Indeed, these responses are often 
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sensitive to personal and social context. Hence, 
any policy support for pre-conceptual testing 
must be informed by wider public consultation 
ensuring choice - rather than essentially 
handing out screening in the guise of testing. 
 4.1   We recommend wider public consultation 
across majority/minority ethnic groups 
on the complex social and ethical issues 
underpinning carrier screening for recessive 
gene disorders, especially within the context 
of the international convention on the rights 
of disabled people. The model followed by 
the Nuffield Council on Bioethics for open 
consultancy/deliberative workshops (eg, 
Children and clinical research and Donor 
conception: ethical aspects of information 
sharing) is a potentially good one to 
follow. Widening such consultation across 
and beyond minority ethnic groups will 
help unpick policy responses that have 
so far been located in a racialized history 
of haemoglobinopathies and politics of 
marginalisation of the health of minority 
ethnic communities. 
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